TCF — Theracryf Income Statement
0.000.00%
- £3.53m
- £1.52m
- £0.40m
Annual income statement for Theracryf, fiscal year end - March 31st, GBP millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.194 | 0 | 0.442 | 0.396 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3.17 | 3.41 | 3.19 | 5.55 | 3.96 |
Operating Profit | -3.17 | -3.21 | -3.19 | -5.1 | -3.57 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -3.17 | -3.21 | -3.17 | -5.01 | -3.57 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.71 | -2.67 | -2.73 | -4.04 | -3.14 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.71 | -2.67 | -2.73 | -4.04 | -3.14 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -2.71 | -2.67 | -2.73 | -4.04 | -3.14 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.021 | -0.018 | -0.01 | -0.015 | -0.011 |